An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases

Biotechnology Advances

Volumn 31, Issue 8, 2013, Pages 1676-1694

  Heng, Boon Chin ^a   Aubel, Dominique ^a,b   Fussenegger, Martin ^a,c  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Disease; G protein; Human; Molecular; Pathology; Receptor

Indexed keywords

G PROTEIN; G-PROTEIN COUPLED RECEPTORS; HIGH-RESOLUTION STRUCTURES; HIGH-THROUGHPUT SCREENING; HUMAN; MOLECULAR; NEURODEGENERATIVE DISORDERS; RECEPTOR;

BINDING ENERGY; DISEASES; PATHOLOGY; PHYSIOLOGY; PROTEINS;

DIAGNOSIS;

BIOTECHNOLOGY; CANCER; DISEASE; DRUG; HOMEOSTASIS; MODELING; PATHOLOGY; PHYSIOLOGY; PROTEIN; SIGNALING;

G PROTEIN COUPLED RECEPTOR; RECEPTOR;

CARDIOVASCULAR DISEASE; COMMUNICABLE DISEASE; DEGENERATIVE DISEASE; DISEASES; G-PROTEIN; HUMAN; IMMUNOPATHOLOGY; METABOLIC DISORDER; MOLECULAR; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

DISEASE; G-PROTEIN; HUMAN; MOLECULAR; PATHOLOGY; RECEPTOR;

CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; METABOLIC DISEASES; NEOPLASMS; NEURODEGENERATIVE DISEASES; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84887999195     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2013.08.017     Document Type: Review

References (349)

1. Aherne C.M., Kewley E.M., Eltzschig H.K. The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta 2011, 1808(5):1329-1339. [May].
2. Aikawa S., Ishii M., Yanagisawa M., Sakakibara Y., Sakurai T. Effect of neuropeptide B on feeding behavior is influenced by endogenous corticotropin-releasing factor activities. Regul Pept 2008, 151(1-3):147-152. [Nov 29].
3. Ali S., Lazennec G. Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 2007, 26(3-4):401-420. [Dec].
4. Anand I., McMurray J., Cohn J.N., Konstam M.A., Notter T., Quitzau K., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364(9431):347-354. [Jul 24-30].
5. Andrade D., Serra R., Svensjö E., Lima A.P., Ramos E.S., Fortes F.S., et al. Trypanosoma cruzi invades host cells through the activation of endothelin and bradykinin receptors: a converging pathway leading to chagasic vasculopathy. Br J Pharmacol 2012, 165(5):1333-1347. [Mar].
6. Arévalo-Martín A., García-Ovejero D., Gómez O., Rubio-Araiz A., Navarro-Galve B., Guaza C., et al. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br J Pharmacol 2008, 153(2):216-225. [Jan].
7. Arevalo-Martin A., Molina-Holgado E., Guaza C. A CB1/CB2 receptor agonist, WIN 55,212-2, exerts its therapeutic effect in a viral autoimmune model of multiple sclerosis by restoring self-tolerance to myelin. Neuropharmacology 2012, 63(3):385-393. [Sep].
8. Arora P., Cuevas B.D., Russo A., Johnson G.L., Trejo J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion. Oncogene 2008, 27(32):4434-4445. [Jul 24].
9. Asano K., Bohlmeyer T.J., Westcott J.Y., Zisman L., Kinugawa K., Good M., et al. Altered expression of endothelin receptors in failing human left ventricles. J Mol Cell Cardiol 2002, 34(7):833-846. [Jul].
10. Ashton J.C. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 2007, 8(5):373-384. [May].
11. Ayers K.L., Thérond P.P. Evaluating Smoothened as a G-protein-coupled receptor for Hedgehog signalling. Trends Cell Biol 2010, 20(5):287-298. [May].
12. Babbitt D.G., Virmani R., Forman M.B. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation 1989, 80(5):1388-1399. [Nov].
13. Bagnato A., Loizidou M., Pflug B.R., Curwen J., Growcott J. Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 2011, 163(2):220-233. [May].
14. Bakshi P., Jin C., Broutin P., Berhane B., Reed J., Mullan M. Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta. Bioorg Med Chem 2009, 17(23):8102-8112. [Dec 1].
15. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4(7):540-550. [Jul].
16. Basu S., Dittel B.N. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 2011, 51(1):26-38. [Oct]. 10.1007/s12026-011-8210-5.
17. Beisser P.S., Lavreysen H., Bruggeman C.A., Vink C. Chemokines and chemokine receptors encoded by cytomegaloviruses. Curr Top Microbiol Immunol 2008, 325:221-242.
18. Belfiore A., Malaguarnera R. Insulin receptor and cancer. Endocr Relat Cancer 2011, 18(4):R125-R147. [Jul 4].
19. Berrino F., De Angelis R., Sant M., Rosso S., Bielska-Lasota M., Coebergh J.W., et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol 2007, 8(9):773-783. [Sep].
20. Beurrier C., Lopez S., Révy D., Selvam C., Goudet C., Lhérondel M., et al. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J 2009, 23(10):3619-3628. [Oct].
21. Bhola N.E., Grandis J.R. Crosstalk between G-protein-coupled receptors and epidermal growth factor receptor in cancer. Front Biosci 2008, 13:1857-1865. [Jan 1].
22. Bittencourt J.C., Elias C.F. Melanin-concentrating hormone and neuropeptide EI projections from the lateral hypothalamic area and zona incerta to the medial septal nucleus and spinal cord: a study using multiple neuronal tracers. Brain Res 1998, 805(1-2):1-19. [Sep 14].
23. Bittencourt J.C., Frigo L., Rissman R.A., Casatti C.A., Nahon J.L., Bauer J.A. The distribution of melanin-concentrating hormone in the monkey brain (Cebus apella). Brain Res 1998, 804(1):140-143. [Aug 31].
24. Bjursell M., Gerdin A.K., Jönsson M., Surve V.V., Svensson L., Huang X.F., et al. G protein-coupled receptor 12 deficiency results in dyslipidemia and obesity in mice. Biochem Biophys Res Commun 2006, 348(2):359-366. [Sep 22].
25. Blázquez C., Chiarlone A., Sagredo O., Aguado T., Pazos M.R., Resel E., et al. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 2011, 134(Pt 1):119-136. [Jan].
26. Bongers G., de Esch I., Leurs R. Molecular pharmacology of the four histamine receptors. Adv Exp Med Biol 2010, 709:11-19.
27. Bost K.L. Tachykinin-mediated modulation of the immune response. Front Biosci 2004, 9:3331-3332. [Sep 1].
28. Boutajangout A., Sigurdsson E.M., Krishnamurthy P.K. Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res 2011, 8(6):666-677. [Sep].
29. Branchek T.A., Smith K.E., Gerald C., Walker M.W. Galanin receptor subtypes. Trends Pharmacol Sci 2000, 21(3):109-117. [Mar].
30. Brekke O.L., Christiansen D., Fure H., Fung M., Mollnes T.E. The role of complement C3 opsonization, C5a receptor, and CD14 in E. coli-induced up-regulation of granulocyte and monocyte CD11b/CD18 (CR3), phagocytosis, and oxidative burst in human whole blood. J Leukoc Biol 2007, 81(6):1404-1413. [Jun].
31. Bretherton-Watt D., Ghatei M.A., Jamal H., Gilbey S.G., Jones P.M., Bloom S.R. The physiology of calcitonin gene-related peptide in the islet compared with that of islet amyloid polypeptide (amylin). Ann N Y Acad Sci 1992, 657:299-312. [Jun 30].
32. Brezillon S., Lannoy V., Franssen J.D., Le Poul E., Dupriez V., Lucchetti J., et al. Identification of natural ligands for the orphan G protein-coupled receptors GPR7 and GPR8. J Biol Chem 2003, 278(2):776-783. [Jan 10].
33. Bristow M.R., Hershberger R.E., Port J.D., Minobe W., Rasmussen R. Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989, 35(3):295-303. [Mar].
34. Bulenger S., Marullo S., Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 2005, 26(3):131-137. [Mar].
35. Bunnett N.W. Protease-activated receptors: how proteases signal to cells to cause inflammation and pain. Semin Thromb Hemost 2006, 32(Suppl. 1):39-48. [Apr].
36. Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 2008, 34(Suppl. 2):S73-S77. [Feb].
37. Campos M.M., Calixto J.B. Neurokinin mediation of edema and inflammation. Neuropeptides 2000, 34(5):314-322. [Oct].
38. Cannon M. The KSHV and other human herpesviral G protein-coupled receptors. Curr Top Microbiol Immunol 2007, 312:137-156.
39. Cao Y., Prescott S.M. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002, 190(3):279-286. [Mar].
40. Chambers A.P., Woods S.C. The role of neuropeptide Y in energy homeostasis. Handb Exp Pharmacol 2012, 209:23-45.
41. Chase T.N., Engber T.M., Mouradian M.M. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994, 44(7 Suppl. 6):S15-S18. [Jul].
42. Chatterjee A., Rathore A., Vidyant S., Kakkar K., Dhole T.N. Chemokines and chemokine receptors in susceptibility to HIV-1 infection and progression to AIDS. Dis Markers 2012, 32(3):143-151.
43. Chen J.K., Taipale J., Cooper M.K., Beachy P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002, 16(21):2743-2748. [Nov 1].
44. Chen Y., Corriden R., Inoue Y., Yip L., Hashiguchi N., Zinkernagel A., et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 2006, 314(5806):1792-1795. [Dec 15].
45. Chen X., Lou G., Meng Z., Huang W. TGR5: a novel target for weight maintenance and glucose metabolism. Exp Diabetes Res 2011, 2011:853501.
46. Chen L., Jin L., Zhou N. An update of novel screening methods for GPCR in drug discovery. Expert Opin Drug Discov 2012, 7(9):791-806. [Sep].
47. Chi H. Sphingosine-1-phosphate and immune regulation: trafficking and beyond. Trends Pharmacol Sci 2011, 32(1):16-24. [Jan].
48. 4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10. ACS Chem Neurosci 2013, 4(1):130-140. [Jan 16].
49. Cohn J.N., Tognoni G., Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345(23):1667-1675. [Dec 6].
50. Cooper C., Reginster J.Y., Cortet B., Diaz-Curiel M., Lorenc R.S., Kanis J.A., et al. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin 2012, 28(3):475-491. [Mar].
51. Coura J.R., Borges-Pereira J. Chagas disease. What is known and what should be improved: a systemic review. Rev Soc Bras Med Trop 2012, 45(3):286-296. [Jun].
52. Cummings D.E., Purnell J.Q., Frayo R.S., Schmidova K., Wisse B.E., Weigle D.S. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001, 50(8):1714-1719. [Aug].
53. Cuomo D., Martella G., Barabino E., Platania P., Vita D., Madeo G., et al. Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. J Neurochem 2009, 109(4):1096-1105. [May].
54. Curtis J.R., Safford M.M. Management of osteoporosis among the elderly with other chronic medical conditions. Drugs Aging 2012, 29(7):549-564. [Jul 1].
55. Dale C., Vergnolle N. Protease signaling to G protein-coupled receptors: implications for inflammation and pain. J Recept Signal Transduct Res 2008, 28(1-2):29-37.
56. Dall'Igna O.P., Porciúncula L.O., Souza D.O., Cunha R.A., Lara D.R. Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity. Br J Pharmacol 2003, 138(7):1207-1209. [Apr].
57. De Ambrogi M., Volpe S., Tamanini C. Ghrelin: central and peripheral effects of a novel peptydil hormone. Med Sci Monit 2003, 9(9):RA217-RA224. [Sep].
58. de Nigris F., Schiano C., Infante T., Napoli C. CXCR4 inhibitors: tumor vasculature and therapeutic challenges. Recent Pat Anticancer Drug Discov 2012, 7(3):251-264. [Sep].
59. De Strooper B., Vassar R., Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol 2010, 6(2):99-107. [Feb].
60. Del Nery E., Juliano M.A., Lima A.P., Scharfstein J., Juliano L. Kininogenase activity by the major cysteinyl proteinase (cruzipain) from Trypanosoma cruzi. J Biol Chem 1997, 272(41):25713-25718. [Oct 10].
61. Della-Zuana O., Audinot V., Levenez V., Ktorza A., Presse F., Nahon J.L., et al. Peripheral injections of melanin-concentrating hormone receptor 1 antagonist S38151 decrease food intake and body weight in rodent obesity models. Front Endocrinol (Lausanne) 2012, 3:160.
62. Deshpande A.D., Harris-Hayes M., Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008, 88(11):1254-1264. [Nov].
63. Després J.P. Body fat distribution and risk of cardiovascular disease: an update. Circulation 2012, 126(10):1301-1313. [Sep 4].
64. Di Virgilio F., Baricordi O.R., Romagnoli R., Baraldi P.G. Leukocyte P2 receptors: a novel target for anti-inflammatory and anti-tumor therapy. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5(1):85-99. [Feb].
65. Dorsam R.T., Gutkind J.S. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007, 7(2):79-94. [Feb].
66. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007, 113(3):546-593. [Mar].
67. Drazen D.L., Vahl T.P., D'Alessio D.A., Seeley R.J., Woods S.C. Effects of a fixed meal pattern on ghrelin secretion: evidence for a learned response independent of nutrient status. Endocrinology 2006, 147(1):23-30. [Jan].
68. Dufton N., Perretti M. Therapeutic anti-inflammatory potential of formyl-peptide receptor agonists. Pharmacol Ther 2010, 127(2):175-188. [Aug].
69. Egido E.M., Hernández R., Leprince J., Chartrel N., Vaudry H., Marco J., et al. 26RFa, a novel orexigenic neuropeptide, inhibits insulin secretion in the rat pancreas. Peptides 2007, 28(4):725-730. [Apr].
70. Eglen R.M., Reisine T. New insights into GPCR function: implications for HTS. Methods Mol Biol 2009, 552:1-13.
71. Ehses J.A., Lee S.S., Pederson R.A., McIntosh C.H. A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion. J Biol Chem 2001, 276(26):23667-23673. [Jun 29].
72. Elste A.P., Petersen I. Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer. J Mol Histol 2010, 41(2-3):89-99. [Apr].
73. Ely S.W., Berne R.M. Protective effects of adenosine in myocardial ischemia. Circulation 1992, 85(3):893-904. [Mar].
74. Engelhardt H., Smits R.A., Leurs R., Haaksma E., de Esch I.J. A new generation of antihistamines: histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Devel 2009, 12(5):628-643. [Sep].
75. Estrada Sánchez A.M., Mejía-Toiber J., Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 2008, 39(3):265-276. [Apr].
76. Feng X.T., Leng J., Xie Z., Li S.L., Zhao W., Tang Q.L. GPR40: a therapeutic target for mediating insulin secretion (review). Int J Mol Med 2012, 30(6):1261-1266. [Dec].
77. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46(4):765-781. [Mar].
78. Ferraguti F., Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res 2006, 326(2):483-504. [Nov].
79. Ferré S., Rimondini R., Popoli P., Reggio R., Pèzzola A., Hansson A.C., et al. Stimulation of adenosine A1 receptors attenuates dopamine D1 receptor-mediated increase of NGFI-A, c-fos and jun-B mRNA levels in the dopamine-denervated striatum and dopamine D1 receptor-mediated turning behavior. Eur J Neurosci 1999, 11(11):3884-3892. [Nov].
80. Ferrero M.E. Purinoceptors in inflammation: potential as anti-inflammatory therapeutic targets. Front Biosci 2011, 16:2172-2186. [Jun 1].
81. Figueroa C.D., Ehrenfeld P., Bhoola K.D. Kinin receptors as targets for cancer therapy. Expert Opin Ther Targets 2012, 16(3):299-312. [Mar].
82. Fischer W.H., Hugli T.E. Regulation of B cell functions by C3a and C3a(desArg): suppression of TNF-alpha, IL-6, and the polyclonal immune response. J Immunol 1997, 159(9):4279-4286. [Nov 1].
83. Fischer O.M., Hart S., Gschwind A., Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003, 31(Pt 6):1203-1208. [Dec].
84. Fischgräbe J., Götte M., Michels K., Kiesel L., Wülfing P. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells. Int J Cancer 2010, 127(3):696-706. [Aug 1].
85. Franco R., Casadó V., Cortés A., Ferrada C., Mallol J., Woods A., et al. Basic concepts in G-protein-coupled receptor homo- and heterodimerization. Scientific World Journal 2007, 7:48-57. [Nov 2].
86. Fraser C.C. G protein-coupled receptor connectivity to NF-kappaB in inflammation and cancer. Int Rev Immunol 2008, 27(5):320-350.
87. Fujimoto W.Y., Ensinck J.W., Merchant F.W., Williams R.H., Smith P.H., Johnson D.G. Stimulation by gastric inhibitory polypeptide of insulin and glucagon secretion by rat islet cultures. Proc Soc Exp Biol Med 1978, 157(1):89-93. [Jan].
88. Fuxe K., Marcellino D., Genedani S., Agnati L. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease. Mov Disord 2007, 22(14):1990-2017. [Oct 31].
89. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006, 46:277-300.
90. Gandhi P.S., Chen Z., Appelbaum E., Zapata F., Di Cera E. Structural basis of thrombin-protease-activated receptor interactions. IUBMB Life 2011, 63(6):375-382. [Jun].
91. Garner A.L., Janda K.D. A small molecule antagonist of ghrelin O-acyltransferase (GOAT). Chem Commun (Camb) 2011, 47(26):7512-7514. [Jul 14].
92. Geldenhuys W.J., Van der Schyf C.J. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev Neurother 2009, 9(7):1073-1085. [Jul].
93. Gelmini S., Mangoni M., Serio M., Romagnani P., Lazzeri E. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. J Endocrinol Invest 2008, 31(9):809-819. [Sep].
94. Gesty-Palmer D., Luttrell L.M. 'Biasing' the parathyroid hormone receptor: a novel anabolic approach to increasing bone mass?. Br J Pharmacol 2011, 164(1):59-67. [Sep].
95. Gesty-Palmer D., Flannery P., Yuan L., Corsino L., Spurney R., Lefkowitz R.J., et al. A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med 2009, 1(1):1ra1. [Oct 7].
96. Giles T.D., Sander G.E., Thomas M.G., Quiroz A.C. Alpha-adrenergic mechanisms in the pathophysiology of left ventricular heart failure-an analysis of their role in systolic and diastolic dysfunction. J Mol Cell Cardiol 1986, 18(Suppl. 5):33-43. [Nov].
97. Gilman A.G. G proteins: transducers of receptor-generated signals. Annu Rev Biochem 1987, 56:615-649.
98. Gloriam D.E., Fredriksson R., Schiöth H.B. The G protein-coupled receptor subset of the rat genome. BMC Genomics 2007, 8:338. [Sep 25].
99. Gould A., Missailidis S. Targeting the hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the hedgehog pathway. Mini Rev Med Chem 2011, 11(3):200-213. [Mar].
100. Greenberg M., Cammack N., Salgo M., Smiley L. HIV fusion and its inhibition in antiretroviral therapy. Rev Med Virol 2004, 14(5):321-337. [Sep-Oct].
101. Gu W., Yan H., Winters K.A., Komorowski R., Vonderfecht S., Atangan L., et al. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther 2009, 331(3):871-881. [Dec].
102. Gurevich E.V., Tesmer J.J., Mushegian A., Gurevich V.V. G protein-coupled receptor kinases: more than just kinases and not only for GPCRs. Pharmacol Ther 2012, 133(1):40-69. [Jan].
103. Gusella J.F., MacDonald M.E. Huntington's disease. Semin Cell Biol 1995, 6(1):21-28. [Feb].
104. Hara T., Hirasawa A., Ichimura A., Kimura I., Tsujimoto G. Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J Pharm Sci 2011, 100(9):3594-3601. [Sep].
105. Harach T., Pols T.W., Nomura M., Maida A., Watanabe M., Auwerx J., et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci Rep 2012, 2:430.
106. Harada K., Sugaya T., Murakami K., Yazaki Y., Komuro I. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. Circulation 1999, 100(20):2093-2099. [Nov 16].
107. Harmar A.J., Fahrenkrug J., Gozes I., Laburthe M., May V., Pisegna J.R., et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 2012, 166(1):4-17. [May].
108. Haskó G., Kuhel D.G., Chen J.F., Schwarzschild M.A., Deitch E.A., Mabley J.G., et al. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 2000, 14(13):2065-2074. [Oct].
109. Hauge-Evans A.C., Richardson C.C., Milne H.M., Christie M.R., Persaud S.J., Jones P.M. A role for kisspeptin in islet function. Diabetologia 2006, 49(9):2131-2135. [Sep].
110. Haupt S., Haupt Y. Importance of p53 for cancer onset and therapy. Anticancer Drugs 2006, 17(7):725-732. [Aug].
111. Hay D.L., Poyner D.R., Sexton P.M. GPCR modulation by RAMPs. Pharmacol Ther 2006, 109(1-2):173-197. [Jan].
112. Haynes A.C., Jackson B., Overend P., Buckingham R.E., Wilson S., Tadayyon M., et al. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides 1999, 20(9):1099-1105.
113. Heimer G., Rivlin-Etzion M., Bar-Gad I., Goldberg J.A., Haber S.N., Bergman H. Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism. J Neurosci 2006, 26(31):8101-8114. [Aug 2].
114. Heller R.S., Kieffer T.J., Habener J.F. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 1997, 46(5):785-791. [May].
115. Heng B.C., Fussenegger M. Design and application of synthetic biology devices for therapy. Synthetic biology - tools and applications 2013, 159-181. Academic Press Inc., London. H. Zhao (Ed.).
116. Hillaire-Buys D., Chapal J., Bertrand G., Petit P., Loubatières-Mariani M.M. Purinergic receptors on insulin-secreting cells. Fundam Clin Pharmacol 1994, 8(2):117-127.
117. Hirashima N., Tsunematsu T., Ichiki K., Tanaka H., Kilduff T.S., Yamanaka A. Neuropeptide B induces slow wave sleep in mice. Sleep 2011, 34(1):31-37. [Jan 1].
118. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 2003, 47(5):401-407. [May].
119. Holst B., Egerod K.L., Jin C., Petersen P.S., Østergaard M.V., Hald J., et al. G protein-coupled receptor 39 deficiency is associated with pancreatic islet dysfunction. Endocrinology 2009, 150(6):2577-2585. [Jun].
120. Holst J.J., Vilsbøll T., Deacon C.F. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 2009, 297(1-2):127-136. [Jan 15].
121. Hondo M., Ishii M., Sakurai T. The NPB/NPW neuropeptide system and its role in regulating energy homeostasis, pain, and emotion. Results Probl Cell Differ 2008, 46:239-256.
122. Hoppler S., Kavanagh C.L. Wnt signalling: variety at the core. J Cell Sci 2007, 120(Pt 3):385-393. [Feb 1].
123. Huang S., Apasov S., Koshiba M., Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997, 90(4):1600-1610. [Aug 15].
124. Huot P., Fox S.H., Brotchie J.M. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011, 95(2):163-212. [Oct].
125. Irlbeck D.M., Amrine-Madsen H., Kitrinos K.M., Labranche C.C., Demarest J.F. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS 2008, 22(12):1425-1431. [Jul 31].
126. Jacobson K.A., Costanzi S. New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. Mol Pharmacol 2012, 82(3):361-371. [Sep].
127. Jolly P.S., Bektas M., Olivera A., Gonzalez-Espinosa C., Proia R.L., Rivera J., et al. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med 2004, 199(7):959-970. [Apr 5].
128. Kailey B., van de Bunt M., Cheley S., Johnson P.R., MacDonald P.E., Gloyn A.L., et al. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells. Am J Physiol Endocrinol Metab 2012, 303(9):E1107-E1116. [Nov 1].
129. Kalyankrishna S., Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006, 24(17):2666-2672. [Jun 10].
130. Kang Y., Wu Z., Lau T.C., Lu X., Liu L., Cheung A.K., et al. CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant. J Biol Chem 2012, 287(20):16499-16509. [May 11].
131. Karim-Kos H.E., de Vries E., Soerjomataram I., Lemmens V., Siesling S., Coebergh J.W. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008, 44(10):1345-1389. [Jul].
132. Kasper M., Regl G., Frischauf A.M., Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer 2006, 42(4):437-445. [Mar].
133. Katanaev V.L. The Wnt/Frizzled GPCR signaling pathway. Biochemistry (Mosc) 2010, 75(12):1428-1434. [Dec].
134. Katoh M., Katoh M. WNT signaling pathway and stem cell signaling network. Clin Cancer Res 2007, 13(14):4042-4045. [Jul 15].
135. Katritch V., Cherezov V., Stevens R.C. Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci 2012, 33(1):17-27. [Jan].
136. Kemmer C., Fluri D.A., Witschi U., Passeraub A., Gutzwiller A., Fussenegger M. A designer network coordinating bovine artificial insemination by ovulation-triggered release of implanted sperms. J Control Release 2011, 150(1):23-29. [Feb 28].
137. Khanapure S.P., Garvey D.S., Janero D.R., Letts L.G. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr Top Med Chem 2007, 7(3):311-340.
138. Kim C.H. Chemokine-chemokine receptor network in immune cell trafficking. Curr Drug Targets Immune Endocr Metabol Disord 2004, 4(4):343-361. [Dec].
139. Kim S.H., Fraser P.E., Westaway D., St George-Hyslop P.H., Ehrlich M.E., Gandy S. Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer's amyloid(beta)42 from isolated intact nerve terminals. J Neurosci 2010, 30(11):3870-3875. [Mar 17].
140. 2+ signaling and phosphatidylinositol 4,5-bisphosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway. Endocrinology 2007, 148(7):3246-3257. [Jul].
141. Kisfalvi K., Eibl G., Sinnett-Smith J., Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 2009, 69(16):6539-6545. [Aug 15].
142. Knop F.K. Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?. Am J Physiol Endocrinol Metab 2010, 299(1):E10-E13. [Jul].
143. Kojima M., Kangawa K. Ghrelin: structure and function. Physiol Rev 2005, 85(2):495-522. [Apr].
144. Koski A.M., Löyttyniemi E., Väänänen H., Laine H., Niskanen L., Nevalainen P.I., et al. The effectiveness of teriparatide in the clinical practice-attenuation of the bone mineral density outcome by increasing age and bisphosphonate pretreatment. Ann Med 2013, 45(3):230-235. [May].
145. Kroeze W.K., Sheffler D.J., Roth B.L. G-protein-coupled receptors at a glance. J Cell Sci 2003, 116(Pt 24):4867-4869. [Dec 15].
146. Kucia M., Reca R., Miekus K., Wanzeck J., Wojakowski W., Janowska-Wieczorek A., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23(7):879-894. [Aug].
147. Kulbe H., Levinson N.R., Balkwill F., Wilson J.L. The chemokine network in cancer-much more than directing cell movement. Int J Dev Biol 2004, 48(5-6):489-496.
148. Kumar R., Balhuizen A., Amisten S., Lundquist I., Salehi A. Insulinotropic and antidiabetic effects of 17β-estradiol and the GPR30 agonist G-1 on human pancreatic islets. Endocrinology 2011, 152(7):2568-2579. [Jul].
149. Laferrère B., Hart A.B., Bowers C.Y. Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake. Obesity (Silver Spring) 2006, 14(6):1056-1063. [Jun].
150. Lagerström M.C., Schiöth H.B. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 2008, 7(4):339-357. [Apr].
151. Lam D.W., LeRoith D. The worldwide diabetes epidemic. Curr Opin Endocrinol Diabetes Obes 2012, 19(2):93-96. [Apr].
152. Lappano R., Maggiolini M. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov 2011, 10(1):47-60. [Jan].
153. Lappano R., Maggiolini M. GPCRs and cancer. Acta Pharmacol Sin 2012, 33(3):351-362. [Mar].
154. Le Y., Wang J.M., Liu X., Kong Y., Hou X., Ruan L., et al. Biologically active peptides interacting with the G protein-coupled formylpeptide receptor. Protein Pept Lett 2007, 14(9):846-853.
155. Lee Y.S., Choi I., Ning Y., Kim N.Y., Khatchadourian V., Yang D., et al. Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 2012, 106(11):1833-1841. [May 22].
156. Lew M. Overview of Parkinson's disease. Pharmacotherapy 2007, 27(12 Pt 2):155S-160S. [Dec].
157. Lezoualc'h F. 5-HT4 receptor and Alzheimer's disease: the amyloid connection. Exp Neurol 2007, 205(2):325-329. [Jun].
158. Li R., Coulthard L.G., Wu M.C., Taylor S.M., Woodruff T.M. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J 2013, 27(3):855-864. [Mar].
159. Liggett S.B. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000, 61(3):167-173. [Sep].
160. Lindsley C.W., Hopkins C.R. Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature. Expert Opin Ther Pat 2012, 22(5):461-481. [May].
161. Ling X., Spaeth E., Chen Y., Shi Y., Zhang W., Schober W., et al. The CXCR4 antagonist AMD3465 regulates oncogenic signaling and invasiveness in vitro and prevents breast cancer growth and metastasis in vivo. PLoS One 2013, 8(3):e58426. 10.1371/journal.pone.0058426.
162. Lohse M.J., Engelhardt S., Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure?. Circ Res 2003, 93(10):896-906. [Nov 14].
163. Lopez O.L. The growing burden of Alzheimer's disease. Am J Manag Care 2011, 17(Suppl. 13):S339-S345. [Nov].
164. Luttrell L.M., Kenakin T.P. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol 2011, 756:3-35.
165. Maeda K., Das D., Nakata H., Mitsuya H. CCR5 inhibitors: emergence, success, and challenges. Expert Opin Emerg Drugs 2012, 17(2):135-145. [Jun].
166. Maletínská L., Matyšková R., Maixnerová J., Sýkora D., Pýchová M., Spolcová A., et al. The Peptidic GHS-R antagonist [d-Lys(3)]GHRP-6 markedly improves adiposity and related metabolic abnormalities in a mouse model of postmenopausal obesity. Mol Cell Endocrinol 2011, 343(1-2):55-62. [Aug 22].
167. Malloy J., Meloni A., Han J. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data. Postgrad Med 2013, 125(3):58-67. [May].
168. Marinissen M.J., Gutkind J.S. G-protein-coupled receptors and signaling networks: emerging paradigms. Trends Pharmacol Sci 2001, 22(7):368-376. [Jul].
169. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009, 284(10):6038-6042. [Mar 6].
170. Mason J.S., Bortolato A., Congreve M., Marshall F.H. New insights from structural biology into the druggability of G protein-coupled receptors. Trends Pharmacol Sci 2012, 33(5):249-260. [May].
171. Mateo Z., Porter J.T. Group II metabotropic glutamate receptors inhibit glutamate release at thalamocortical synapses in the developing somatosensory cortex. Neuroscience 2007, 146(3):1062-1072. [May 25].
172. Matise M.P., Joyner A.L. Gli genes in development and cancer. Oncogene 1999, 18(55):7852-7859. [Dec 20].
173. Matsuya T., Takuma K., Sato K., Asai M., Murakami Y., Miyoshi S., et al. Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model. J Pharmacol Sci 2007, 103(3):329-332. [Mar].
174. Matusiak D., Glover S., Nathaniel R., Matkowskyj K., Yang J., Benya R.V. Neuromedin B and its receptor are mitogens in both normal and malignant epithelial cells lining the colon. Am J Physiol Gastrointest Liver Physiol 2005, 288(4):G718-G728. [Apr].
175. Maussang D., Vischer H.F., Leurs R., Smit M.J. Herpes virus-encoded G protein-coupled receptors as modulators of cellular function. Mol Pharmacol 2009, 76(4):692-701. [Oct].
176. May L.T., Avlani V.A., Sexton P.M., Christopoulos A. Allosteric modulation of G protein-coupled receptors. Curr Pharm Des 2004, 10(17):2003-2013.
177. Mayorga A.J., Cousins M.S., Trevitt J.T., Conlan A., Gianutsos G., Salamone J.D. Characterization of the muscarinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats. Eur J Pharmacol 1999, 364(1):7-11. [Jan 1].
178. McIntosh V.J., Lasley R.D. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant?. J Cardiovasc Pharmacol Ther 2012, 17(1):21-33. [Mar].
179. McWhinney C.D., Dudley M.W., Bowlin T.L., Peet N.P., Schook L., Bradshaw M., et al. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol 1996, 310(2-3):209-216. [Aug 29].
180. Meggs L.G., Coupet J., Huang H., Cheng W., Li P., Capasso J.M., et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res 1993, 72(6):1149-1162. [Jun].
181. Mela F., Marti M., Dekundy A., Danysz W., Morari M., Cenci M.A. Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 2007, 101(2):483-497. [Apr].
182. Mericq V., Cassorla F., Bowers C.Y., Avila A., Gonen B., Merriam G.R. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. J Pediatr Endocrinol Metab 2003, 16(7):981-985. [Sep].
183. Métayé T., Perdrisot R., Kraimps J.L. GRKs and arrestins: the therapeutic pathway?. Med Sci (Paris) 2006, 22(5):537-543. [May].
184. Miller J.R. The Wnts. Genome Biol 2002, 3(1). [REVIEWS3001].
185. Miller N.R., Daniels R.N., Lee D., Conn P.J., Lindsley C.W. Synthesis and SAR of N-(4-(4-alklylpiperazin-1-yl)phenyl) benzamides as muscarinic acetylcholine receptor subtype 1 (M1) antagonists. Bioorg Med Chem Lett 2010, 20(7):2174-2177. [Apr 1].
186. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003, 3(8):582-591. [Aug].
187. Mizuno Y., Nomoto M., Kondo T., Hasegawa K., Murata M., Takeuchi M., et al. Transdermal rotigotine in early stage Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Mov Disord 2013, [Jun 25, Epub ahead of print]. 10.1002/mds.25537.
188. Moens K., Heimberg H., Flamez D., Huypens P., Quartier E., Ling Z., et al. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996, 45(2):257-261. [Feb].
189. Mondal M.S., Yamaguchi H., Date Y., Shimbara T., Toshinai K., Shimomura Y., et al. A role for neuropeptide W in the regulation of feeding behavior. Endocrinology 2003, 144(11):4729-4733. [Nov].
190. Montanya E. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opin Pharmacother 2012, 13(10):1451-1467. [Jul].
191. Mountjoy K.G. Distribution and function of melanocortin receptors within the brain. Adv Exp Med Biol 2010, 681:29-48.
192. Movsesyan V.A., Stoica B.A., Faden A.I. MGLuR5 activation reduces beta-amyloid-induced cell death in primary neuronal cultures and attenuates translocation of cytochrome c and apoptosis-inducing factor. J Neurochem 2004, 89(6):1528-1536. [Jun].
193. Mu J., Jiang G., Brady E., Dallas-Yang Q., Liu F., Woods J., et al. Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice. Diabetologia 2011, 54(9):2381-2391. [Sep].
194. Muñoz A., Carlsson T., Tronci E., Kirik D., Björklund A., Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Exp Neurol 2009, 219(1):298-307. [Sep].
195. Murakami T., Yamamoto N. Role of CXCR4 in HIV infection and its potential as a therapeutic target. Future Microbiol 2010, 5(7):1025-1039. [Jul]. 10.2217/fmb.10.67. Review.
196. Murph M.M., Hurst-Kennedy J., Newton V., Brindley D.N., Radhakrishna H. Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells. Mol Cancer Res 2007, 5(11):1201-1211. [Nov].
197. Nair R.P., Ren J. Pharmacotherapy of obesity - benefit, bias and hyperbole. Curr Med Chem 2009, 16(15):1888-1897.
198. Nakasone T., Kumakura S., Yamamoto M., Murakami T., Yamamoto N. Single oral administration of the novel CXCR4 antagonist, KRH-3955, induces an efficient and long-lasting increase of white blood cell count in normal macaques, and prevents CD4 depletion in SHIV-infected macaques: a preliminary study. Med Microbiol Immunol 2013, 202(2):175-182. [Apr].
199. Ni Y., Zhao X., Bao G., Zou L., Teng L., Wang Z., et al. Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med 2006, 12(12):1390-1396. [Dec].
200. Niño H., Rodríguez-Borges J.E., García-Mera X., Prado-Prado F. Review of synthesis, assay, and prediction of β and γ-secretase inhibitors. Curr Top Med Chem 2012, 12(8):828-844.
201. Niswender C.M., Johnson K.A., Weaver C.D., Jones C.K., Xiang Z., Luo Q., et al. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol 2008, 74(5):1345-1358. [Nov].
202. Nitsch R.M., Deng M., Growdon J.H., Wurtman R.J. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J Biol Chem 1996, 271(8):4188-4194. [Feb 23].
203. Obeso J.A., Marin C., Rodriguez-Oroz C., Blesa J., Benitez-Temiño B., Mena-Segovia J., et al. The basal ganglia in Parkinson's disease: current concepts and unexplained observations. Ann Neurol 2008, 64(Suppl. 2):S30-S46. [Dec].
204. Ohishi T., Yoshida S. The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin Investig Drugs 2012, 21(3):321-328. [Mar].
205. Olanow C.W., Brundin P. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. Mov Disord 2013, 28(1):31-40. [Jan].
206. O'Leary D.M., Movsesyan V., Vicini S., Faden A.I. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol 2000, 131(7):1429-1437. [Dec].
207. Olson T.S., Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002, 283(1):R7-R28. [Jul].
208. O'Mahony L., Akdis M., Akdis C.A. Regulation of the immune response and inflammation by histamine and histamine receptors. J Allergy Clin Immunol 2011, 128(6):1153-1162. [Dec].
209. Oshikawa S., Tanoue A., Koshimizu T.A., Kitagawa Y., Tsujimoto G. Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach. Mol Pharmacol 2004, 65(3):623-629. [Mar].
210. Ossovskaya V.S., Bunnett N.W. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004, 84(2):579-621. [Apr].
211. Pai R., Szabo I.L., Soreghan B.A., Atay S., Kawanaka H., Tarnawski A.S. PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochem Biophys Res Commun 2001, 286(5):923-928. [Sep 7].
212. Palus S., Schur R., Akashi Y.J., Bockmeyer B., Datta R., Halem H., et al. Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One 2011, 6(11):e26865.
213. Panetta R., Greenwood M.T. Physiological relevance of GPCR oligomerization and its impact on drug discovery. Drug Discov Today 2008, 13(23-24):1059-1066. [Dec].
214. Paradis P., Dali-Youcef N., Paradis F.W., Thibault G., Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A 2000, 97(2):931-936. [Jan 18].
215. Park J.K., Song J.H., He T.C., Nam S.W., Lee J.Y., Park W.S. Overexpression of Wnt-2 in colorectal cancers. Neoplasma 2009, 56(2):119-123.
216. Patacchini R., Maggi C.A. Tachykinin receptors and receptor subtypes. Arch Int Pharmacodyn Ther 1995, 329(1):161-184. [Jan-Feb].
217. Pedersen W.A., McCullers D., Culmsee C., Haughey N.J., Herman J.P., Mattson M.P. Corticotropin-releasing hormone protects neurons against insults relevant to the pathogenesis of Alzheimer's disease. Neurobiol Dis 2001, 8(3):492-503. [Jun].
218. Pellicciari R., Gioiello A., Macchiarulo A., Thomas C., Rosatelli E., Natalini B., et al. Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity. J Med Chem 2009, 52(24):7958-7961. [Dec 24].
219. Perez D.M. From plants to man: the GPCR "tree of life". Mol Pharmacol 2005, 67(5):1383-1384. [May].
220. Perez D.M., Doze V.A. Cardiac and neuroprotection regulated by α(1)-adrenergic receptor subtypes. J Recept Signal Transduct Res 2011, 31(2):98-110. [Apr].
221. Pettersson M., Ahrén B. Gastrin releasing peptide (GRP): effects on basal and stimulated insulin and glucagon secretion in the mouse. Peptides 1987, 8(1):55-60. [Jan-Feb].
222. Pfeffer M.A., Braunwald E., Moyé L.A., Basta L., Brown E.J., Cuddy T.E., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992, 327(10):669-677. [Sep 3].
223. Phillips L.K., Prins J.B. Update on incretin hormones. Ann N Y Acad Sci 2011, 1243:E55-E74. [Dec].
224. Pinna A., Pontis S., Borsini F., Morelli M. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse 2007, 61(8):606-614. [Aug].
225. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., et al. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons. Neuroscience 2001, 106(3):579-587.
226. Pitson S.M., Xia P., Leclercq T.M., Moretti P.A., Zebol J.R., Lynn H.E., et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med 2005, 201(1):49-54. [Jan 3].
227. Pitt B., Poole-Wilson P.A., Segal R., Martinez F.A., Dickstein K., Camm A.J., et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355(9215):1582-1587. [May 6].
228. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol 2012, 1:4(5). [May].
229. Põld M., Zhu L.X., Sharma S., Burdick M.D., Lin Y., Lee P.P., et al. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer. Cancer Res 2004, 64(5):1853-1860. [Mar 1].
230. Pollakis G., Paxton W.A. HIV-1 (co)receptors: implications for vaccine and therapy design. Curr Pharm Des 2010, 16(33):3701-3715.
231. Proudfoot A.E., Power C.A., Rommel C., Wells T.N. Strategies for chemokine antagonists as therapeutics. Semin Immunol 2003, 15(1):57-65. [Feb].
232. Pyne N.J., Tonelli F., Lim K.G., Long J.S., Edwards J., Pyne S. Sphingosine 1-phosphate signalling in cancer. Biochem Soc Trans 2012, 40(1):94-100. [Feb].
233. Qin L., Raggatt L.J., Partridge N.C. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol Metab 2004, 15(2):60-65. [Mar].
234. Qureshi S.A., Rios Candelore M., Xie D., Yang X., Tota L.M., Ding V.D., et al. A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 2004, 53(12):3267-3273. [Dec].
235. Rabiet M.J., Macari L., Dahlgren C., Boulay F. N-formyl peptide receptor 3 (FPR3) departs from the homologous FPR2/ALX receptor with regard to the major processes governing chemo-attractant receptor regulation, expression at the cell surface, and phosphorylation. J Biol Chem 2011, 286(30):26718-26731. [Jul 29].
236. Rainsford K.D. Anti-inflammatory drugs in the 21st century. Subcell Biochem 2007, 42:3-27.
237. Rat D., Schmitt U., Tippmann F., Dewachter I., Theunis C., Wieczerzak E., et al. Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J 2011, 25(9):3208-3218. [Sep].
238. Rayasam G.V., Tulasi V.K., Davis J.A., Bansal V.S. Fatty acid receptors as new therapeutic targets for diabetes. Expert Opin Ther Targets 2007, 11(5):661-671. [May].
239. Regitz-Zagrosek V., Friedel N., Heymann A., Bauer P., Neuss M., Rolfs A., et al. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 1995, 91(5):1461-1471. [Mar 1].
240. Reich R., Martin G.R. Identification of arachidonic acid pathways required for the invasive and metastatic activity of malignant tumor cells. Prostaglandins 1996, 51(1):1-17. [Jan].
241. Reiner A., Lafferty D.C., Wang H.B., Del Mar N., Deng Y.P. The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice. Neurobiol Dis 2012, 47(1):75-91. [Jul].
242. Reiter E., Lefkowitz R.J. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab 2006, 17(4):159-165. [May-Jun].
243. Richard D.E., Vouret-Craviari V., Pouysségur J. Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene 2001, 20(13):1556-1562. [Mar 26].
244. Rising T.J., Lewis S. A species comparison of the histamine H2-receptor on mast cells and basophils. Agents Actions 1982, 12(3):263-267. [Jul].
245. Ritter S.L., Hall R.A. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol 2009, 10(12):819-830. [Dec].
246. Rivera J., Proia R.L., Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 2008, 8(10):753-763. [Oct].
247. Romero G., von Zastrow M., Friedman P.A. Role of PDZ proteins in regulating trafficking, signaling, and function of GPCRs: means, motif, and opportunity. Adv Pharmacol 2011, 62:279-314.
248. Roosenburg S., Laverman P., van Delft F.L., Boerman O.C. Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors. Amino Acids 2011, 41(5):1049-1058. [Nov].
249. Rosenbaum D.M., Rasmussen S.G., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459(7245):356-363. [May 21].
250. Rosenthal T., Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens 2009, 23(10):623-635. [Oct].
251. Rossner S., Ueberham U., Schliebs R., Perez-Polo J.R., Bigl V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol 1998, 56(5):541-569. [Dec].
252. Rothmeier A.S., Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol 2012, 34(1):133-149. [Jan].
253. Rozengurt E., Sinnett-Smith J., Kisfalvi K. Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 2010, 16(9):2505-2511. [May 1].
254. Ruiz de Azua I., Gautam D., Jain S., Guettier J.M., Wess J. Critical metabolic roles of β-cell M3 muscarinic acetylcholine receptors. Life Sci 2012, 91(21-22):986-991. [Nov 27].
255. Russo O., Cachard-Chastel M., Rivière C., Giner M., Soulier J.L., Berthouze M., et al. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease. J Med Chem 2009, 52(8):2214-2225. [Apr 23].
256. Rylander D., Iderberg H., Li Q., Dekundy A., Zhang J., Li H., et al. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol Dis 2010, 39(3):352-361. [Sep].
257. Saito Y., Nagasaki H. The melanin-concentrating hormone system and its physiological functions. Results Probl Cell Differ 2008, 46:159-179.
258. Saito Y., Nothacker H.P., Wang Z., Lin S.H., Leslie F., Civelli O. Molecular characterization of the melanin-concentrating-hormone receptor. Nature 1999, 400(6741):265-269. [Jul 15].
259. Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92(4):573-585. [Feb 20].
260. Salmon J.E., Cronstein B.N. Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol 1990, 145(7):2235-2240. [Oct 1].
261. Salmon J.E., Brogle N., Brownlie C., Edberg J.C., Kimberly R.P., Chen B.X., et al. Human mononuclear phagocytes express adenosine A1 receptors. A novel mechanism for differential regulation of Fc gamma receptor function. J Immunol 1993, 151(5):2775-2785. [Sep 1].
262. Schiefer J., Sprünken A., Puls C., Lüesse H.G., Milkereit A., Milkereit E., et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res 2004, 1019(1-2):246-254. [Sep 3].
263. Schiöth H.B., Fredriksson R. The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen Comp Endocrinol 2005, 142(1-2):94-101. [May 15].
264. Schruefer R., Lutze N., Schymeinsky J., Walzog B. Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. Am J Physiol Heart Circ Physiol 2005, 288(3):H1186-H1192. [Mar].
265. Scotter E.L., Goodfellow C.E., Graham E.S., Dragunow M., Glass M. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. Br J Pharmacol 2010, 160(3):747-761. [Jun].
266. Selassie M., Sinha A.C. The epidemiology and aetiology of obesity: a global challenge. Best Pract Res Clin Anaesthesiol 2011, 25(1):1-9. [Mar].
267. Selbach O., Haas H.L. Hypocretins: the timing of sleep and waking. Chronobiol Int 2006, 23(1-2):63-70.
268. Shearman L.P., Camacho R.E., Sloan Stribling D., Zhou D., Bednarek M.A., Hreniuk D.L., et al. Chronic MCH-1 receptor modulation alters appetite, body weight and adiposity in rats. Eur J Pharmacol 2003, 475(1-3):37-47. [Aug 15].
269. Shimizu N., Tanaka A., Oue A., Mori T., Apichartpiyakul C., Hoshino H. A short amino acid sequence containing tyrosine in the N-terminal region of G protein-coupled receptors is critical for their potential use as co-receptors for human and simian immunodeficiency viruses. J Gen Virol 2008, 89(Pt 12):3126-3136. [Dec].
270. Shoichet B.K., Kobilka B.K. Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol Sci 2012, 33(5):268-272. [May].
271. Silva B.C., Costa A.G., Cusano N.E., Kousteni S., Bilezikian J.P. Catabolic and anabolic actions of parathyroid hormone on the skeleton. J Endocrinol Invest 2011, 34(10):801-810. [Nov]. 10.3275/7925.
272. Singh G., Davenport A.P. Neuropeptide B and W: neurotransmitters in an emerging G-protein-coupled receptor system. Br J Pharmacol 2006, 148(8):1033-1041. [Aug].
273. Singh S., Sadanandam A., Nannuru K.C., Varney M.L., Mayer-Ezell R., Bond R., et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res 2009, 15(7):2380-2386. [Apr 1].
274. Sitaraman S.V., Merlin D., Wang L., Wong M., Gewirtz A.T., Si-Tahar M., et al. Neutrophil-epithelial crosstalk at the intestinal lumenal surface mediated by reciprocal secretion of adenosine and IL-6. J Clin Invest 2001, 107(7):861-869. [Apr].
275. Skaper S.D. Alzheimer's disease and amyloid: culprit or coincidence?. Int Rev Neurobiol 2012, 102:277-316.
276. Slinger E., Langemeijer E., Siderius M., Vischer H.F., Smit M.J. Herpes virus-encoded GPCRs rewire cellular signaling. Mol Cell Endocrinol 2011, 331(2):179-184. [Jan 15].
277. Soos S., Petervari E., Szekely M., Jech-Mihalffy A., Balasko M. Complex catabolic effects of central alpha-MSH infusion in rats of altered nutritional states: differences from leptin. J Mol Neurosci 2011, 43(2):209-216. [Feb]. 10.1007/s12031-010-9462-6.
278. Spampinato S.F., Molinaro G., Merlo S., Iacovelli L., Caraci F., Battaglia G., et al. Estrogen receptors and type 1 metabotropic glutamate receptors are interdependent in protecting cortical neurons against β-amyloid toxicity. Mol Pharmacol 2012, 81(1):12-20. [Jan].
279. Strieter R.M., Belperio J.A., Phillips R.J., Keane M.P. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 2004, 14(3):195-200. [Jun].
280. Strieter R.M., Burdick M.D., Mestas J., Gomperts B., Keane M.P., Belperio J.A. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006, 42(6):768-778. [Apr].
281. Sun L., Ye R.D. Role of G protein-coupled receptors in inflammation. Acta Pharmacol Sin 2012, 33(3):342-350. [Mar].
282. Sun Y., Wu F., Sun F., Huang P. Adenosine promotes IL-6 release in airway epithelia. J Immunol 2008, 180(6):4173-4181. [Mar 15].
283. Suresh P., Wanchu A. Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics. J Postgrad Med 2006, 52(3):210-217. [Jul-Sep].
284. Taborsky G.J., Mundinger T.O. Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia. Endocrinology 2012, 153(3):1055-1062. [Mar].
285. Tallaksen-Greene S.J., Kaatz K.W., Romano C., Albin R.L. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Res 1998, 780(2):210-217. [Jan 12].
286. Tanaka H., Yoshida S., Oshima H., Minoura H., Negoro K., Yamazaki T., et al. Chronic treatment with novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. J Pharmacol Exp Ther 2013, 346(3):443-452. [Sep].
287. Tang C.M., Insel P.A. GPCR expression in the heart; "new" receptors in myocytes and fibroblasts. Trends Cardiovasc Med 2004, 14(3):94-99. [Apr].
288. Tendera M., Gaszewska-Zurek E., Parma Z., Ponikowski P., Jankowska E., Kawecka-Jaszcz K., et al. The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. Clin Res Cardiol 2012, 101(7):585-591. [Jul].
289. Teng L., Zhao J., Wang F., Ma L., Pei G. A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis. Cell Res 2010, 20(2):138-153. [Feb].
290. Teske J.A., Billington C.J., Kotz C.M. Hypocretin/orexin and energy expenditure. Acta Physiol (Oxf) 2010, 198(3):303-312. [Mar].
291. Teuscher C., Subramanian M., Noubade R., Gao J.F., Offner H., Zachary J.F., et al. Central histamine H3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc Natl Acad Sci U S A 2007, 104(24):10146-10151. [Jun 12].
292. Thathiah A., Spittaels K., Hoffmann M., Staes M., Cohen A., Horré K., et al. The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science 2009, 323(5916):946-951. [Feb 13].
293. Thomas S.M., Bhola N.E., Zhang Q., Contrucci S.C., Wentzel A.L., Freilino M.L., et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006, 66(24):11831-11839. [Dec 15].
294. Thompson M.D., Cole D.E., Jose P.A. Pharmacogenomics of G protein-coupled receptor signaling: insights from health and disease. Methods Mol Biol 2008, 448:77-107.
295. Thurmond R.L., Gelfand E.W., Dunford P.J. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discov 2008, 7(1):41-53. [Jan].
296. Tilley D.G., Rockman H.A. Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. Expert Rev Cardiovasc Ther 2006, 4(3):417-432. [May].
297. Tornehave D., Kristensen P., Rømer J., Knudsen L.B., Heller R.S. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. J Histochem Cytochem 2008, 56(9):841-851. [Sep].
298. Trejo J. Internal PDZ, ligands: novel endocytic recycling motifs for G protein-coupled receptors. Mol Pharmacol 2005, 67(5):1388-1390. [May].
299. Trincavelli M.L., Daniele S., Martini C. Adenosine receptors: what we know and what we are learning. Curr Top Med Chem 2010, 10(9):860-877.
300. Trujillo G., Zhang J., Habiel D.M., Ge L., Ramadass M., Ghebrehiwet B., et al. Cofactor regulation of C5a chemotactic activity in physiological fluids. Requirement for the vitamin D binding protein, thrombospondin-1 and its receptors. Mol Immunol 2011, 49(3):495-503. [Dec].
301. Tsopanoglou N.E., Maragoudakis M.E. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost 2004, 30(1):63-69. [Feb].
302. Tu S.M. Origin of cancers. Clinical perspectives and implications of a stem-cell theory of cancer. Cancer Treat Res 2010, 154:v-239.
303. Tzavara E.T., Bymaster F.P., Davis R.J., Wade M.R., Perry K.W., Wess J., et al. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB J 2004, 18(12):1410-1412. [Sep].
304. Uchio N., Doi M., Matsuo M., Yamazaki F., Mizoro Y., Hondo M., et al. Circadian characteristics of mice depleted with GPR7. Biomed Res 2009, 30(6):357-364. [Dec].
305. Ulven T. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front Endocrinol (Lausanne) 2012, 3:111.
306. Umezu-Goto M., Tanyi J., Lahad J., Liu S., Yu S., Lapushin R., et al. Lysophosphatidic acid production and action: validated targets in cancer?. J Cell Biochem 2004, 92(6):1115-1140. [Aug 15].
307. Vacca F., Bagnato A., Catt K.J., Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000, 60(18):5310-5317. [Sep 15].
308. Vallano A., Fernandez-Duenas V., Pedros C., Arnau J.M., Ciruela F. An update on adenosine A2A receptors as drug target in Parkinson's disease. CNS Neurol Disord Drug Targets 2011, 10(6):659-669. [Sep 1].
309. Vicenzi E., Liò P., Poli G. The puzzling role of CXCR4 in human immunodeficiency virus infection. Theranostics 2013, 3(1):18-25.
310. Vischer H.F., Vink C., Smit M.J. A viral conspiracy: hijacking the chemokine system through virally encoded pirated chemokine receptors. Curr Top Microbiol Immunol 2006, 303:121-154.
311. Vogt W. Anaphylatoxins: possible roles in disease. Complement 1986, 3(3):177-188.
312. von Kügelgen I. Pharmacological profiles of cloned mammalian P2Y-receptor subtypes. Pharmacol Ther 2006, 110(3):415-432. [Jun].
313. Wang R., Dashwood R.H. Endothelins and their receptors in cancer: identification of therapeutic targets. Pharmacol Res 2011, 63(6):519-524. [Jun].
314. Wang D., Dubois R.N. Prostaglandins and cancer. Gut 2006, 55(1):115-122. [Jan].
315. Wang J., Osaka T., Inoue S. Energy expenditure by intracerebroventricular administration of orexin to anesthetized rats. Neurosci Lett 2001, 315(1-2):49-52. [Nov 23].
316. Wang Q., Liang X., Wang S. Intra-islet glucagon secretion and action in the regulation of glucose homeostasis. Front Physiol 2012, 3:485.
317. Ward B.K., Magno A.L., Walsh J.P., Ratajczak T. The role of the calcium-sensing receptor in human disease. Clin Biochem 2012, 45(12):943-953. [Aug].
318. Watanabe M., Houten S.M., Mataki C., Christoffolete M.A., Kim B.W., Sato H., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439(7075):484-489. [Jan 26].
319. Wente M.N., Keane M.P., Burdick M.D., Friess H., Büchler M.W., Ceyhan G.O., et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006, 241(2):221-227. [Sep 28].
320. Werneck A.L., Rosso A.L., Vincent M.B. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. Arq Neuropsiquiatr 2009, 67(2B):407-412. [Jun].
321. Weroha S.J., Haluska P. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am 2012, 41(2):335-350. [Jun, vi].
322. Wheeler-Jones C.P., Farrar C., Garonna E. Protease-activated receptors, cyclo-oxygenases and pro-angiogenic signalling in endothelial cells. Biochem Soc Trans 2009, 37(Pt 6):1179-1183. [Dec].
323. Widenmaier S.B., Kim S.J., Yang G.K., De Los Reyes T., Nian C., Asadi A., et al. A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS One 2010, 5(3):e9590. [Mar 9].
324. Wilen C.B., Tilton J.C., Doms R.W. Molecular mechanisms of HIV entry. Adv Exp Med Biol 2012, 726:223-242.
325. Wilkin T.J., Gulick R.M. CCR5 antagonism in HIV infection: current concepts and future opportunities. Annu Rev Med 2012, 63:81-93.
326. Willie J.T., Chemelli R.M., Sinton C.M., Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001, 24:429-458.
327. Wittner M., Christ G.J., Huang H., Weiss L.M., Hatcher V.B., Morris S.A., et al. Trypanosoma cruzi induces endothelin release from endothelial cells. J Infect Dis 1995, 171(2):493-497. [Feb].
328. Woo A.Y., Xiao R.P. β-Adrenergic receptor subtype signaling in heart: from bench to bedside. Acta Pharmacol Sin 2012, 33(3):335-341. [Mar].
329. Woodruff T.M., Nandakumar K.S., Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011, 48(14):1631-1642. [Aug].
330. Wright K.L., Duncan M., Sharkey K.A. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 2008, 153(2):263-270. [Jan].
331. Wu P., Yang L., Shen X. The relationship between GPR40 and lipotoxicity of the pancreatic β-cells as well as the effect of pioglitazone. Biochem Biophys Res Commun 2010, 403(1):36-39. [Dec 3].
332. Xaus J., Valledor A.F., Cardó M., Marquès L., Beleta J., Palacios J.M., et al. Adenosine inhibits macrophage colony-stimulating factor-dependent proliferation of macrophages through the induction of p27kip-1 expression. J Immunol 1999, 163(8):4140-4149. [Oct 15].
333. Xiang Y., Kobilka B.K. Myocyte adrenoceptor signaling pathways. Science 2003, 300(5625):1530-1532. [Jun 6].
334. Xiang Z., Thompson A.D., Jones C.K., Lindsley C.W., Conn P.J. Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson's disease. J Pharmacol Exp Ther 2012, 340(3):595-603. [Mar].
335. Xiong Y., Guo J., Candelore M.R., Liang R., Miller C., Dallas-Yang Q., et al. Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes. J Med Chem 2012, 55(13):6137-6148. [Jul 12].
336. Xu Y., Elmquist J.K., Fukuda M. Central nervous control of energy and glucose balance: focus on the central melanocortin system. Ann N Y Acad Sci 2011, 1243:1-14. [Dec].
337. Yamanaka A., Sakurai T., Katsumoto T., Yanagisawa M., Goto K. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 1999, 849(1-2):248-252. [Dec 4].
338. Yang G., Rosen D.G., Liu G., Yang F., Guo X., Xiao X., et al. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 2010, 16(15):3875-3886. [Aug 1].
339. Ye H., Daoud-El Baba M., Peng R.W., Fussenegger M. A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice. Science 2011, 332(6037):1565-1568. [Jun 24].
340. Ye H., Charpin-El Hamri G., Zwicky K., Christen M., Folcher M., Fussenegger M. Pharmaceutically controlled designer circuit for the treatment of the metabolic syndrome. Proc Natl Acad Sci U S A 2013, 110(1):141-146. [Jan 2].
341. Yue J.T., Burdett E., Coy D.H., Giacca A., Efendic S., Vranic M. Somatostatin receptor type 2 antagonism improves glucagon and corticosterone counterregulatory responses to hypoglycemia in streptozotocin-induced diabetic rats. Diabetes 2012, 61(1):197-207. [Jan].
342. Zaibi M.S., Stocker C.J., O'Dowd J., Davies A., Bellahcene M., Cawthorne M.A., et al. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett 2010, 584(11):2381-2386. [Jun 3].
343. Zampeli E., Tiligada E. The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol 2009, 157(1):24-33. [May].
344. Zeron M.M., Chen N., Moshaver A., Lee A.T., Wellington C.L., Hayden M.R., et al. Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci 2001, 17(1):41-53. [Jan].
345. Zhang R., Xie X. Tools for GPCR drug discovery. Acta Pharmacol Sin 2012, 33(3):372-384. [Mar].
346. Zhang Y., Qian Y., Lu W., Chen X. The G protein-coupled receptor 87 is necessary for p53-dependent cell survival in response to genotoxic stress. Cancer Res 2009, 69(15):6049-6056. [Aug 1].
347. Zhou W. The new face of anaphylatoxins in immune regulation. Immunobiology 2012, 217(2):225-234. [Feb].
348. Zhou T.J., Chen J., Mokotoff M., Ball E.D. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs 2004, 15(10):921-927. [Nov].
349. Zuo J., Currin A., Griffin B.D., Shannon-Lowe C., Thomas W.A., Ressing M.E., et al. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog 2009, 5(1):e1000255. [Jan].